These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8261772)

  • 1. Bioequivalence revisited: non-parametric analysis of two-period cross-over studies.
    Wijnand HP
    Comput Methods Programs Biomed; 1993 Aug; 40(4):249-59. PubMed ID: 8261772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the assessment of bioequivalence in a two-period cross-over design.
    Wijnand HP
    Comput Methods Programs Biomed; 1992 Mar; 37(2):151-7. PubMed ID: 1643857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates of bioequivalence programs (including statistical power approximated by Student's t).
    Wijnand HP
    Comput Methods Programs Biomed; 1994 Apr; 42(4):275-81. PubMed ID: 7924274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robustness of bioequivalence procedures under Box-Cox alternatives.
    Xiao W; Barron AM; Liu J
    J Biopharm Stat; 1997 Mar; 7(1):135-55. PubMed ID: 9056594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S51-8. PubMed ID: 1601532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers.
    Niopas I; Daftsios AC; Nikolaidis N
    Arzneimittelforschung; 2002; 52(3):182-6. PubMed ID: 11963645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of the bioequivalence of a new isosorbide dinitrate tablet formulation compared with the standard preparation].
    Metzner JE; Buchberger D; Häring N; Läuter J
    Arzneimittelforschung; 1997 Jun; 47(6):719-26. PubMed ID: 9281301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1991 Jan; 29(1):1-8. PubMed ID: 2004861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bias of two one-sided tests procedures in assessment of bioequivalence.
    Liu JP; Weng CS
    Stat Med; 1995 Apr; 14(8):853-61. PubMed ID: 7644864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence of two commercial preparations of trimethoprim/sulfamethoxazole: a randomized, single-dose, single-blind, crossover trial.
    Alonso Campero R; Bernardo Escudero R; Del Cisne Valle Alvarez D; González de la Parra M; Namur Montalvo S; Burke Fraga V; Silva Hernandez R; De Lago Acosta A
    Clin Ther; 2007 Feb; 29(2):326-33. PubMed ID: 17472824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mini-computer programs for bioequivalence testing of pharmaceutical drug formulations in two-way cross-over studies. Including a survey of current parametric evaluation techniques.
    Wijnand HP; Timmer CJ
    Comput Programs Biomed; 1983; 17(1-2):73-88. PubMed ID: 6607152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
    Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM
    Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple BASIC program for the calculation of nonparametric confidence intervals in bioequivalence testing.
    Meineke I
    Comput Methods Programs Biomed; 1987 Feb; 24(1):65-71. PubMed ID: 3829651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The assessment of bioequivalence in a two-period cross-over design: development of a simple BASIC program.
    Meineke I; de Mey C
    Comput Methods Programs Biomed; 1991 Jun; 35(2):151-3. PubMed ID: 1914453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choice of student's t- or Wilcoxon-based confidence intervals for assessment of average bioequivalence.
    Hauck WW; Hauschke D; Diletti E; Bois FY; Steinijans VW; Anderson S
    J Biopharm Stat; 1997 Mar; 7(1):179-89. PubMed ID: 9056597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized double-blind comparison of the effects of isosorbide dinitrate retard, verapamil sustained-release, and their combination on myocardial ischemic episodes.
    Friedensohn A; Meshulam R; Schlesinger Z
    Cardiology; 1991; 79 Suppl 2():31-40. PubMed ID: 1760827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris. A randomized, double-blind, cross-over study. The Swedish Multicentre Group.
    Nordlander R; Walter M
    Eur Heart J; 1994 Jan; 15(1):108-13. PubMed ID: 8174569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
    Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
    Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992 Aug; 30(8):287-90. PubMed ID: 1526691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects.
    Niopas I; Daftsios AC; Nikolaidis N
    Int J Clin Pharmacol Ther; 2001 May; 39(5):224-8. PubMed ID: 11380069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.